European Medicines Agency’s (EMA) human medicines committee has recommended granting an extension of indication for the COVID-19 vaccine Comirnaty to include use in children aged 5 to 11. The vaccine, developed by BioNTech and Pfizer, is already approved for use in adults and children aged 12 and above. In children from 5 to 11 years of age, the dose of Comirnaty will be lower than that used in people aged 12 and above (10 µg compared with 30 µg).
The reluctance or refusal to accept Covid-19 vaccinations can be tackled by a five-pronged strategy to addressing the behavioural and socio-demographic factors behind vaccine hesitancy. Writing in the Journal of the Royal Society of Medicine, a group of population health, demographic, epidemiology and behavioural scientists propose an approach focused on confidence, complacency, convenience, communication and context. While confidence in the safety and efficacy of vaccines is crucial, they write, complacency, particularly among younger people and those of lower socioeconomic status, is
WHO today validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing. The vaccine is produced by the Beijing-based pharmaceutical company Sinovac. “The world desperately needs multiple COVID-19 vaccines to address the huge access inequity across the globe,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge manufacturers to participate in the COVAX Facility, share their